17.69
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors - Nasdaq
ADMA Biologics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
ADMA Biologics, Inc. Rings the Opening Bell - Nasdaq
Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
(ADMA) Proactive Strategies - news.stocktradersdaily.com
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - Yahoo Finance
(ADMA) Investment Analysis - news.stocktradersdaily.com
Implied Volatility Surging for ADMA Biologics Stock Options - TradingView
Will Strong Asceniv Sales Drive ADMA Biologics Further? - Yahoo Finance
ADMA Biologics Becomes Oversold - Nasdaq
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios - Insider Monkey
ADMA Biologics Shares Plunge 2.10% Amid Insider Selling - AInvest
ADMA Biologics: A Rare Buying Opportunity Amid Insider Selling - AInvest
(ADMA) On The My Stocks Page - news.stocktradersdaily.com
ADMA Makes Notable Cross Below Critical Moving Average - Nasdaq
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? - sharewise
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) - Seeking Alpha
ADMA Biologics Stock Soars Amid Biotech Growth Nasdaq Composite Gains - Kalkine Media
The 8.3% return this week takes ADMA Biologics' (NASDAQ:ADMA) shareholders three-year gains to 964% - simplywall.st
ADMA Biologics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – ADMA - ACCESS Newswire
Adma Biologics director sells $213,100 in stock - Investing.com Australia
Adma Biologics director sells $213,100 in stock By Investing.com - Investing.com South Africa
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? - Nasdaq
When (ADMA) Moves Investors should Listen - news.stocktradersdaily.com
adma biologics holds annual meeting, elects directors and approves proposals - Investing.com Australia
adma biologics holds annual meeting, elects directors and approves proposals By Investing.com - Investing.com South Africa
ADMA Biologics Holds Annual Stockholders Meeting - TipRanks
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - sharewise
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
Cetera Investment Advisers Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics director sells $182,635 in common stock - Investing.com Australia
Adma Biologics director sells $182,635 in common stock By Investing.com - Investing.com South Africa
Bank of America Corp DE Has $13.14 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Exploring High Growth Tech Stocks In The US May 2025 - Yahoo
Are Options Traders Betting on a Big Move in ADMA Biologics Stock? - The Globe and Mail
Are Options Traders Betting On A Big Move In ADMA Biologics Stock? - Barchart.com
BNP Paribas Financial Markets Sells 674,016 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Ameriprise Financial Inc. Acquires 88,542 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
(ADMA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
FY2025 EPS Estimates for ADMA Biologics Decreased by Analyst - Defense World
Amid Bumpy Biotech Trade, I'm Eyeing These Two Stocks - TheStreet Pro
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics (NASDAQ:ADMA) Rating Lowered to “Sell” at StockNews.com - Defense World
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - The Globe and Mail
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - MSN
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):